ArriVent BioPharma (AVBP) Net Equity Issued and Repurchased (2023 - 2026)

ArriVent BioPharma has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at $54.7 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased rose 739.84% year-over-year to $54.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.9 million (down 50.09% YoY) and the FY2025 annual result came in at $202.6 million, up 8.97% from the prior year.
• Net Equity Issued and Repurchased improved to $54.7 million in Q1 2026 per AVBP's latest filing, from $34.7 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $185.6 million in Q1 2024 and troughed at -$24000.0 in Q2 2023.
• A 4-year average of $54.4 million and a median of $39.8 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2025 and 2026: Net Equity Issued and Repurchased plunged 96.49% in 2025, then jumped 739.84% in 2026.
• Over 4 years, Net Equity Issued and Repurchased stood at -$24000.0 in 2023, then surged by 773562.5% to $185.6 million in 2024, then plunged by 81.33% to $34.7 million in 2025, then surged by 57.9% to $54.7 million in 2026.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $54.7 million, $34.7 million, and $6.5 million for Q1 2026, Q4 2025, and Q1 2025 respectively.